Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the most promising biotech stocks to buy according to hedge funds. During the second quarter, Wealth Enhancement Advisory Services LLC trimmed its ...
Hosted on MSN
Alnylam Pharma Secures $500M Credit Agreement
Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Alnylam Pharma ( (ALNY)) has issued an ...
The company was one of many to get letters last month from the US Food and Drug Administration calling out what the agency believes are misleading commercials.
3don MSN
Alnylam Pharmaceuticals, Inc. (ALNY) Reports $492M Amvuttra Sales, Raises 2025 Revenue Guidance
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a leading biotech company specializing in RNA interference (RNAi) therapeutics, is advancing treatments for rare and prevalent diseases, notably ...
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) ranks among the best biotech stocks to buy. RBC Capital maintained its Outperform rating for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on September 19 and ...
Alnylam Pharmaceuticals ( NASDAQ: ALNY) has pulled a television ad for its drug Amvuttra (vutrisiran) after the U.S. FDA determined the spot was misleading. Amvuttra is approved for two heart ...
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best performing large cap stocks to buy. On September 29, Alnylam Pharmaceuticals announced new data analyses from the HELIOS-B Phase 3 study ...
Alnylam joins Illumina and NashBio’s Alliance for Genomic Discovery to expand its 250,000 genome dataset and fuel RNAi research.
Transcription factors are the most powerful genes in our body. They are master regulators and have been implicated in our biggest diseases, even aging itself. Yet, many in the pharmaceutical industry ...
George Tidmarsh, head of the FDA’s Center for Drug Evaluation and Research, wrote that the ad incorrectly suggested patients "can be carefree" about their heart condition and "misleadingly suggests ...
Trump, who has long promised import taxes on pharmaceutical drugs, took to Truth Social on Thursday reiterating his intent to levy tariffs on pharma companies unless they break ground on US ...
Rnai Therapeutics Market To Hit $8.8B By 2033, Driven By Rare & Cardiovascular Diseases & Sirna And Delivery Innovations. therapeutics represent one of the most exciting frontiers in precision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback